← Back to Screener
Enliven Therapeutics, Inc. Common Stock (ELVN)
Price$37.51
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)70.11%
Price vs S&P 500 (4W)-10.08%
VGM Score73.33
Market Capitalization$2.41B
All Metrics
Book Value / Share (Quarterly)$7.45
P/TBV (Annual)6.60x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.08
Price vs S&P 500 (YTD)146.01%
EPS (TTM)$-1.66
10-Day Avg Trading Volume0.59M
EPS Excl Extra (TTM)$-1.66
EPS (Annual)$-1.83
ROI (Annual)-22.56%
Cash / Share (Quarterly)$7.43
ROA (Last FY)-21.78%
EBITD / Share (TTM)$-1.93
ROE (5Y Avg)-27.62%
Cash Flow / Share (Annual)$-1.19
P/B Ratio5.32x
P/B Ratio (Quarterly)5.17x
Net Income / Employee (Annual)$-1,728,200
ROA (TTM)-20.41%
EV / EBITDA (TTM)612.32x
EPS Incl Extra (Annual)$-1.83
Current Ratio (Annual)28.66x
Quick Ratio (Quarterly)39.38x
3-Month Avg Trading Volume1.00M
52-Week Price Return123.06%
EV / Free Cash Flow (Annual)319.79x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.35
52-Week High$48.53
EPS Excl Extra (Annual)$-1.83
CapEx CAGR (5Y)51.19%
Tangible BV CAGR (5Y)52.86%
26-Week Price Return86.04%
Quick Ratio (Annual)27.92x
13-Week Price Return33.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)40.32x
Enterprise Value$2.28B
Book Value / Share Growth (5Y)57.49%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.78
3-Month Return Std Dev65.29%
Net Income / Employee (TTM)$-1,646,300
ROE (Last FY)-22.56%
EPS Basic Excl Extra (Annual)$-1.83
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.66
ROI (TTM)-21.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$20.43
Price vs S&P 500 (52W)94.85%
Year-to-Date Return156.95%
5-Day Price Return-4.74%
EPS Normalized (Annual)$-1.83
ROA (5Y Avg)-25.70%
Month-to-Date Return-4.03%
Cash Flow / Share (TTM)$-0.72
EBITD / Share (Annual)$-2.11
LT Debt / Equity (Annual)0.08x
ROI (5Y Avg)-27.62%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.66
P/TBV (Quarterly)1.84x
P/B Ratio (Annual)1.99x
Book Value / Share (Annual)$7.73
Price vs S&P 500 (13W)23.85%
Beta0.52x
Revenue / Share (TTM)$0.00
ROE (TTM)-21.04%
52-Week Low$14.79
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.38est. -0.47
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELVNEnliven Therapeutics, Inc. Common Stock | — | — | B | $37.51 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule targeted therapies for cancer. Its pipeline includes ELVN-001, which targets BCR-ABL fusion in chronic myeloid leukemia, and ELVN-002, a HER2 inhibitor designed to address both wild-type and mutant forms of the protein.